Case Study

Next Level Digitalization in Small Molecule Production

Small molecule production sites require a different level of automation and digitalization to address the upcoming trend of more personalized drug production and faster innovation cycles. Currently, most of these production sites lack the necessary infrastructure and capabilities to be ready for this new era. Our client wanted to understand their current maturity compared to industry peers and develop a roadmap towards a higher degree of digitalization and a more efficient product introduction.

Our client faced the impact of personalized drug production requirements for their small molecule production sites and a low level of automation and digitalization in the current setup. Additionally, our client lacked a clear target and roadmap on how to advance their current level more systematically.

Client Challenge

Our team of manufacturing experts assessed the maturity of the manufacturing sites, including all key processes, systems being used, and digital and automation technologies in place. We benchmarked the site's' maturity against industry peers to identify key action areas. Based on this assessment, we developed a roadmap and clear targets in collaboration with our client to improve the current level of maturity.

Our Approach

A clear roadmap based on industry best practices towards a higher degree of digital maturity, including an underlying investment and ROI plan, provides security for global investment decisions.

The Impact